Mubadala Bio Acquires Full Ownership of Yas Holding Healthcare's IDS and GMSC

Abu Dhabi, UAE – 17 February 2026 – Mubadala Bio, a life sciences company committed to advancing better health outcomes for the UAE and beyond, announced that it has finalized the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) from Yas Holding’s GlobalOne Healthcare Holding, following the initial 80% acquisition at the end of 2024.

The completion of this transaction reflects Mubadala Bio’s continued progress in building a vertically integrated life sciences platform in the UAE. By bringing together biopharmaceutical manufacturing and pharmaceutical logistics under a unified strategy, the company is reinforcing its commitment to strengthening the national life sciences ecosystem.

Low Ping, Group CEO of Yas Holding, commented: “We are pleased to confirm Mubadala Bio’s full ownership and control of IDS and GMSC.  The proven capability and reach of both companies will help ensure resilience and efficiency not just across Mubadala Bio’s growing life sciences platform, but also our national healthcare supply chain”.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio ,said: “Completing the full acquisition of IDS and GMSC represents an important milestone in Mubadala Bio’s journey. As a national champion in life sciences, Mubadala Bio continues to strengthen its presence and expand its ability to deliver meaningful impact across the UAE.”

Through full ownership of IDS and GMSC, Mubadala Bio advances its mission to strengthen national drug security, reinforce critical pharmaceutical distribution networks, and help build a robust, integrated life sciences ecosystem that supports the UAE’s ambition for a resilient, innovation-driven healthcare sector.